Trial Profile

A phase II/III international trial of Tinostamustine for glioblastoma patients

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 11 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Nov 2025 New trial record
10 Nov 2025 Accoridng to a Purdue Pharma media release, FDA has granted orphan drug designation (ODD) to its pipeline drug tinostamustine for the treatment of malignant gliomas.
17 Sep 2025 Accoridng to a Purdue Pharma media release, company is looking forward for Investigational New Drug Application (IND) and Clinical Trial Application (CTA) submissions necessary to include tinostamustine in innovative and patient-centric adaptive trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com